Abstract
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are common therapeutic agents for EGFR mutation-positive advanced non-small-cell lung cancer. There has been no report of rhabdomyolysis caused by an overdose of EGFR-TKIs. We herein review the existing literature on the subject and report a rare case of rhabdomyolysis due to an overdose of gefitinib, an EGFR-TKI.
Keywords:
EGFR-TKI; overdose; rhabdomyolysis.
MeSH terms
-
Antineoplastic Agents* / adverse effects
-
Carcinoma, Non-Small-Cell Lung* / drug therapy
-
ErbB Receptors / genetics
-
Gefitinib / adverse effects
-
Humans
-
Lung Neoplasms* / drug therapy
-
Mutation
-
Protein Kinase Inhibitors / therapeutic use
-
Quinazolines / adverse effects
-
Rhabdomyolysis* / chemically induced
-
Rhabdomyolysis* / drug therapy
Substances
-
Antineoplastic Agents
-
Protein Kinase Inhibitors
-
Quinazolines
-
ErbB Receptors
-
Gefitinib